Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Hirak Pahari, Amruth Raj, Ambreen Sawant, Dipak S Ahire, Raosaheb Rathod, Chetan Rathi, Tushar Sankalecha, Sachin Palnitkar, Vikram Raut
BACKGROUND: Liver transplantation (LT) for hepatocellular carcinoma (HCC) has been widely researched and is well established worldwide. The cornerstone of this treatment lies in the various criteria formulated by expert consensus and experience. The variations among the criteria are staggering, and the short- and long-term out comes are controversial. AIM: To study the differences in the current practices of LT for HCC at different centers in India and discuss their clinical implications in the future...
March 18, 2024: World Journal of Transplantation
#2
JOURNAL ARTICLE
Hanna Hong, Chase J Wehrle, Mingyi Zhang, Sami Fares, Henry Stitzel, David Garib, Bassam Estfan, Suneel Kamath, Smitha Krishnamurthi, Wen Wee Ma, Teodora Kuzmanovic, Elizabeth Azzato, Emrullah Yilmaz, Jamak Modaresi Esfeh, Maureen Whitsett Linganna, Mazhar Khalil, Alejandro Pita, Andrea Schlegel, Jaekeun Kim, R Matthew Walsh, Charles Miller, Koji Hashimoto, David Choon Hyuck Kwon, Federico Aucejo
INTRODUCTION: Circulating tumor DNA (ctDNA) is emerging as a promising, non-invasive diagnostic and surveillance biomarker in solid organ malignancy. However, its utility before and after liver transplant (LT) for patients with primary and secondary liver cancers is still underexplored. METHODS: Patients undergoing LT for hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and colorectal liver metastases (CRLM) with ctDNA testing were included. CtDNA testing was conducted pre-transplant, post-transplant, or both (sequential) from 11/2019 to 09/2023 using Guardant360, Guardant Reveal, and Guardant360 CDx...
February 25, 2024: Cancers
#3
JOURNAL ARTICLE
Kevin Tak-Pan Ng, Jiang Liu, Oscar Wai-Ho Yeung, Li Pang, Hoi Chung Shiu, Hui Liu, Xin Xiang Yang, Albert Chi-Yan Chan, Tiffany Cho-Lam Wong, Chung Mau Lo, Kwan Man
BACKGROUND: Cytokines are key regulators of post-transplant inflammation responses which reconstitute post-transplant hepatic and systemic environments to influence the likelihood of tumor relapse. This study investigated the prognostic value of post-transplant cytokines on tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC). METHODS: A retrospective analysis was conducted in prospectively collected 150 adult HCC patients who received liver transplantation from 1997 to 2015...
August 5, 2023: Hepatology International
#4
JOURNAL ARTICLE
Bhrugun Anisetti, Ahmed K Ahmed, Tucker Coston, Lindsay Gardner, Umair Majeed, Jordan Reynolds, Hani Babiker
Recurrent hepatocellular carcinoma (HCC) poses a significant challenge after liver transplantation, affecting approximately 10-23% of patients with a median onset of 13 months post-transplantation. Extrahepatic involvement, such as lung, bone, adrenal glands, peritoneum, lymph nodes, and central nervous system (CNS), is commonly observed among transplant recipients with HCC recurrence. Notably, vascular invasion (VI), including microvascular invasion (MiVI) and macrovascular invasion (MVI), substantially increase the risk of recurrence by 2...
December 2023: Clinical Journal of Gastroenterology
#5
JOURNAL ARTICLE
Resmi A Charalel, Alvin I Mushlin, Xinyan Zheng, Jialin Mao, Ruth Carlos, Robert S Brown, Brett Fortune, Adam D Talenfeld, David C Madoff, Said Ibrahim, Matthew S Johnson, Art Sedrakyan
PURPOSE: To compare secondary outcomes following ablation (AB), surgical resection (SR) and liver transplant (LT) for small hepatocellular carcinomas including resource utilization and adverse event (AE) rates. MATERIALS AND METHODS: Using Surveillance, Epidemiology, and End Results Program-Medicare, HCCs less than 5 cm that were treated with AB, SR, or LT in 2009 to 2016 (n = 1,067) were identified using Healthcare Common Procedure Coding System codes through Medicare claims...
July 17, 2023: Journal of Vascular and Interventional Radiology: JVIR
#6
Patrick Gidley, Anand Patel, Guliz A Barkan, Anugayathri Jawahar
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, and liver transplantation is usually curative. HCC recurrences are rare after curative treatment options, although they are prevalent depending on various risk factors. We present a 71-year-old female patient with an unusual pattern of disease progression following a curative liver transplant with a metastatic presentation in the absence of alpha-fetoprotein elevation after 3 years of disease-free clinical presentation. We present this case to emphasize the importance of intermittent cross-sectional imaging in addition to ultrasound screening in HCC surveillance...
July 2023: Indian Journal of Radiology & Imaging
#7
JOURNAL ARTICLE
Islam B Mohamed, Mohamed Saleh Ismail, Ahmed El Sabagh, Ahmed M Afifi Abdelwahab, Efstathia Polychronopoulou, Yong-Fang Kuo, Manal Hassan, John A Goss, Fasiha Kanwal, Prasun K Jalal
BACKGROUND AND AIMS: Contrast-enhanced cross-sectional imaging is the cornerstone in the diagnosis, staging, and management of HCC, including eligibility for liver transplantation (LT). Radiological-histopathological discordance may lead to improper staging and may impact patient outcomes. We aimed to assess the radiological-histopathological discordance at the time of LT in HCC patients and its impact on the post-LT outcomes. METHODS: We analyzed further the effect of 6-month waiting policy on the discordance...
June 16, 2023: Cancer Medicine
#8
JOURNAL ARTICLE
Benjamin V Tran, Dimitrios Moris, Daniela Markovic, Hamed Zaribafzadeh, Ricardo Henao, Quirino Lai, Sander S Florman, Parissa Tabrizian, Brandy Haydel, Richard M Ruiz, Goran B Klintmalm, David D Lee, C Burcin Taner, Maarouf Hoteit, Matthew H Levine, Umberto Cillo, Alessandro Vitale, Elizabeth C Verna, Karim J Halazun, Amit D Tevar, Abhinav Humar, William C Chapman, Neeta Vachharajani, Federico Aucejo, Jan Lerut, Olga Ciccarelli, Mindie H Nguyen, Marc L Melcher, Andre Viveiros, Benedikt Schaefer, Maria Hoppe-Lotichius, Jens Mittler, Trevor L Nydam, James F Markmann, Massimo Rossi, Constance Mobley, Mark Ghobrial, Alan N Langnas, Carol A Carney, Jennifer Berumen, Gabriel T Schnickel, Debra L Sudan, Johnny C Hong, Abbas Rana, Christopher M Jones, Thomas M Fishbein, Ronald W Busuttil, Andrew S Barbas, Vatche G Agopian
HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains an important need. Clinico-radiologic and pathologic data of 4981 patients with HCC undergoing LT from the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine and Gray competing risk analysis and machine learning algorithms (Random Survival Forest and Classification and Regression Tree models) identified variables to model HCC recurrence...
April 10, 2023: Liver Transplantation
#9
JOURNAL ARTICLE
Jun-Bo Li, Yuan-Yuan Zhao, Chen Dai, Dong Chen, Lai Wei, Bo Yang, Zhi-Shui Chen
OBJECTIVE: We aimed to identify new, more accurate risk factors of liver transplantation for liver cancer through using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: Using the SEER database, we identified patients that had undergone surgical resection for non-metastatic hepatocellular carcinoma (HCC) and subsequent liver transplantation between 2010 and 2017. Overall survival (OS) was estimated using Kaplan-Meier plotter. Cox proportional hazards regression modelling was used to identify factors independently associated with recurrent disease [presented as adjusted hazard ratios (HR) with 95% CIs]...
April 2, 2023: Current Medical Science
#10
REVIEW
Riccardo Nevola, Rachele Ruocco, Livio Criscuolo, Angela Villani, Maria Alfano, Domenico Beccia, Simona Imbriani, Ernesto Claar, Domenico Cozzolino, Ferdinando Carlo Sasso, Aldo Marrone, Luigi Elio Adinolfi, Luca Rinaldi
Hepatocellular carcinoma (HCC) is the most frequent liver neoplasm, and its incidence rates are constantly increasing. Despite the availability of potentially curative treatments (liver transplantation, surgical resection, thermal ablation), long-term outcomes are affected by a high recurrence rate (up to 70% of cases 5 years after treatment). HCC recurrence within 2 years of treatment is defined as "early" and is generally caused by the occult intrahepatic spread of the primary neoplasm and related to the tumor burden...
February 28, 2023: World Journal of Gastroenterology: WJG
#11
Neal Modi, Kristen Dougherty, Mustafa Nazzal
Extrahepatic malignancies are a relatively rare incidental finding during liver transplant work-up that provides a significant barrier to continued transplant evaluation and requires treatment to limit the risk of recurrence. There have only been 11 previously reported cases of pre-liver transplant renal cell carcinoma (RCC), of which all underwent partial or radical nephrectomy. Percutaneous cryoablation therapy has been gaining acceptance as a curative treatment alternative for RCC and is a new therapeutic standard for patients who are poor candidates for surgical resection...
December 2022: Curēus
#12
JOURNAL ARTICLE
Jyoti Sehjal, Linda D Sharples, Ruth H Keogh, Kate Walker, Andreas Prachalias, Nigel Heaton, Tommy Ivanics, Jan van der Meulen, David Wallace
BACKGROUND: Accurately identifying time-varying differences in the hazard of all-cause mortality after liver transplantation (LT) between recipients with and without hepatocellular carcinoma (HCC) may inform patient selection and organ allocation policies as well as post-LT surveillance protocols. METHODS: A UK population-based study was carried out using 9586 LT recipients. The time-varying association between HCC and post-LT all-cause mortality was estimated using an adjusted flexible parametric model (FPM) and expressed as hazard ratios (HRs)...
November 1, 2022: Transplantation
#13
JOURNAL ARTICLE
Roberto Rossotti, Marco Merli, Chiara Mazzarelli, Riccardo Maria De Carlis, Giovanna Travi, Marta Vecchi, Raffaella Viganò, Andrea Lauterio, Alessandro Raimondi, Luca Saverio Belli, Luciano Gregorio De Carlis, Massimo Puoti
BACKGROUND: Liver transplantation (LT) represents the best therapeutic option for hepatocellular carcinoma (HCC) and end-stage liver disease (ESLD). Although HIV infection does not seem to lower survival rates, HCV and HCC recurrence appear more harmful. AIMS: To compare the overall survival after LT; evaluate the impact of anti-HCV direct-acting agents (DAA); assess the rate of HCC recurrence in HIV-positive and negative patients. METHODS: Subjects with HCV/HBV infection who underwent LT for HCC or ESLD from 2012 to 2019 were retrospectively evaluated...
May 26, 2022: Digestive and Liver Disease
#14
JOURNAL ARTICLE
Kelley G Núñez, Tyler Sandow, Jai Patel, Mina Hibino, Daniel Fort, Ari J Cohen, Paul Thevenot
Due to active hepatocellular carcinoma (HCC) surveillance, many patients are diagnosed with early-stage disease and are usually amendable to curative treatments. These patients lack poor prognostic factors associated with Milan Criteria and alpha fetoprotein (AFP) biomarker levels. There are currently limited strategies to assess prognosis in the patients who remain at risk of post-treatment HCC progression. In a cohort of liver transplant (LT) candidates with HCC, this study seeks to identify factors prior to liver-directed therapy (LDT) associated with time to progression (TTP)...
March 25, 2022: Cancers
#15
JOURNAL ARTICLE
Charlotte Costentin, Federico Piñero, Helena Degroote, Andrea Notarpaolo, Ilka F Boin, Karim Boudjema, Cinzia Baccaro, Luis G Podestá, Philippe Bachellier, Giuseppe Maria Ettorre, Jaime Poniachik, Fabrice Muscari, Fabrizio Dibenedetto, Sergio Hoyos Duque, Ephrem Salame, Umberto Cillo, Sebastian Marciano, Claire Vanlemmens, Stefano Fagiuoli, Patrizia Burra, Hans Van Vlierberghe, Daniel Cherqui, Quirino Lai, Marcelo Silva, Fernando Rubinstein, Christophe Duvoux
Background & Aims: Patients with hepatocellular carcinoma (HCC) are selected for liver transplantation (LT) based on pre-LT imaging ± alpha-foetoprotein (AFP) level, but discrepancies between pre-LT tumour assessment and explant are frequent. Our aim was to design an explant-based recurrence risk reassessment score to refine prediction of recurrence after LT and provide a framework to guide post-LT management. Methods: Adult patients who underwent transplantation between 2000 and 2018 for HCC in 47 centres were included...
May 2022: JHEP reports: innovation in hepatology
#16
REVIEW
Mignote Yilma, Varun Saxena, Neil Mehta
PURPOSE OF REVIEW: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the United States (U.S.).1 The purpose of this review is to highlight published models that predict development of HCC and estimate risk of HCC recurrence after treatments. RECENT FINDINGS: There have been several models created for both de novo HCC and HCC recurrence, with the more recent models using a combination of age, sex, decompensation, and laboratory values (platelet count, albumin, bilirubin), and liver disease etiology to predict both 5 and 10-year HCC incidence...
January 2022: Current Gastroenterology Reports
#17
Kornelia Morisson-Sarapak, Maciej Wrzesiński, Samir Zeair, Marta Wawrzynowicz-Syczewska
Liver transplantation (LTx) is an accepted method of hepatocellular carcinoma (HCC) treatment in cirrhotic patients; however, it has many limitations, and there is a substantial risk of recurrence. Most relapses occur within the first 2 posttransplant years. We aimed to present a late extrahepatic recurrence of HCC 10 years after LTx, and we discuss the possible risk factors and ways to improve transplantation results. A 68-year-old patient with liver cirrhosis and HCC on the background of chronic HCV and past HBV infection was transplanted urgently due to the rapid decompensation...
September 2021: Case Reports in Oncology
#18
JOURNAL ARTICLE
Amelia J Hessheimer, Ana Magdalena Vargas-Martinez, Marta Trapero-Bertran, Miquel Navasa, Constantino Fondevila
OBJECTIVE: Assess cost-effectiveness and -utility associated with post-transplant HCC surveillance compared to standard follow-up. SUMMARY BACKGROUND DATA: Despite lack of prospective clinical data, expert consensus recommends post-transplant surveillance to detect hepatocellular carcinoma (HCC) recurrence in a latent phase, while it might be amenable to curative-intent therapy. METHODS: A Markov-based transition model was created to estimate life expectancy and quality-of-life among liver transplant patients undergoing HCC surveillance...
November 11, 2021: Annals of Surgery
#19
JOURNAL ARTICLE
Yucel Aydin, Ali Riza Koksal, Paul Thevenot, Srinivas Chava, Zahra Heidari, Dong Lin, Tyler Sandow, Krzysztof Moroz, Mansour A Parsi, John Scott, Ari Cohen, Srikanta Dash
Background and Aims: Hepatocellular carcinoma (HCC) developing in the context of preexisting cirrhosis is characterized by impaired autophagy that results in increased exosome release. This study was conducted to determine whether circulating exosomes expressing glypican 3 (GPC3) could be utilized as a biomarker for HCC detection and treatment response in patients with cirrhosis. Methods: Immunohistochemistry was performed to assess p62 and GPC3 expression in the lesion and adjacent tissue from cirrhosis with HCC...
2021: Journal of Hepatocellular Carcinoma
#20
JOURNAL ARTICLE
Mamatha Bhat, Sergi Clotet-Freixas, Cristina Baciu, Elisa Pasini, Ahmed Hammad, Tommy Ivanics, Shelby Reid, Amirhossein Azhie, Marc Angeli, Anand Ghanekar, Sandra Fischer, Gonzalo Sapisochin, Ana Konvalinka
BACKGROUND AND AIMS: Liver transplantation (LT) can be offered to patients with Hepatocellular carcinoma (HCC) beyond Milan criteria. However, there are currently limited molecular markers on HCC explant histology to predict recurrence, which arises in up to 20% of LT recipients. The goal of our study was to derive a combined proteomic/transcriptomic signature on HCC explant predictive of recurrence post-transplant using unbiased, high-throughput approaches. METHODS: Patients who received a LT for HCC beyond Milan criteria in the context of hepatitis B cirrhosis were identified...
November 18, 2021: Clinical Proteomics
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
